Zhang, Qi

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

Serine ADP-ribosylation depends on HPF1

Bonfiglio, J. J., Fontana, P., Zhang, Q., Colby, T., Gibbs-Seymour, I., Atanassov, I., Bartlett, E., Zaja, R., Ahel, I., & Matic, I. (2017) · Molecular Cell

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 352

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 158

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Han, L., Cavazos, A., Baran, N., Zhang, Q., Kuruvilla, V. M., Gay, J. P., Feng, N., Battula, V. L., Kantarjian, H. M., Daver, N. G., et al. (2019) · Blood

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 19